Venetoclax

{{DrugProjectFormSinglePage |authorTag=Martin Nino [1] |genericName=Venetoclax |aOrAn=a |drugClass=BCL-2 inhibitor |indicationType=treatment |indication=of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial |adverseReactions=neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue (≥20%) |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content)